We addressed the questions of how cerebral glucose transport and phosphorylation change under acute hypoglycemia and what the underlying mechanisms of adaptation are. Methods: Quantitative 18 F-FDG PET combined with the acquisition of real-time arterial input function was performed on mice. Hypoglycemia was induced and maintained by insulin infusion. PET data were analyzed with the 2-tissue-compartment model for 18 F-FDG, and the results were evaluated with Michaelis-Menten saturation kinetics. Results: Glucose clearance from plasma to brain (K 1,glc ) and the phosphorylation rate constant increased with decreasing plasma glucose (G p ), in particular at a G p of less than 2.5 mmol/L. Estimated cerebral glucose extraction ratios taking into account an increased cerebral blood flow (CBF) at a G p of less than 2 mmol/L were between 0.14 and 0.79. CBF-normalized K 1,glc values were in agreement with saturation kinetics. Phosphorylation rate constants indicated intracellular glucose depletion at a G p of less than 2-3 mmol/L. When brain regions were compared, glucose transport under hypoglycemia was lowest in the hypothalamus. Conclusion: Alterations in glucose transport and phosphorylation, as well as intracellular glucose depletion, under acute hypoglycemia can be modeled by saturation kinetics taking into account an increase in CBF. Distinct transport kinetics in the hypothalamus may be involved in its glucose-sensing function.
Bl ood-borne glucose is the major source of energy for neuronal activity. The rate-determining processes involved in cerebral glucose consumption are glucose transport by hexose transporters (GLUTs) and glucose phosphorylation by hexokinase I (1). Both processes underlie Michaelis-Menten saturation kinetics and can adapt to some extent to chronic hypo-or hyperglycemia. Studies in rats have revealed several possible processes by which the brain adapts to glucose deprivation during acute, recurrent, or chronic hypoglycemia. Glucose permeability of the blood-brain barrier (BBB) is increased in models of chronic hypoglycemia. Amplified synthesis and translocation of GLUT1 to the plasma membrane of microvascular endothelial cells have been demonstrated (2) (3) (4) . In addition, upregulation of neuronal GLUT3 expression is likely to be involved in the brain's adaptation to chronic hypoglycemia (4, 5) .
Less is known about adaptations under acute hypoglycemia. Cerebral blood flow (CBF) and, therefore, glucose delivery are increased at a plasma glucose level (G p ) of less than 2 mmol/L (6) . Increased glucose permeability of the BBB and in particular translocation of GLUT1 to the cell surface have been suggested as causal mechanisms for elevated transport (6) (7) (8) . Awareness of acute hypoglycemia is a vital response to low G p . Hypoglycemia unawareness is a life-threatening problem in patients with type 1 insulin-treated diabetes of long duration and repeated episodes of hypoglycemia. There is ample evidence that the hypothalamus has a glucosesensing function. Although GLUT1 is the major glucose transporter at the BBB in general, some regions in the hypothalamus contain high levels of GLUT2 (9) . Two major features of GLUT2 may be involved in glucose sensing. GLUT2 has a higher Michaelis-Menten constant K T than GLUT1 (10) , and a glucose-sensing receptor function was described for an intracellular sequence of GLUT2 (9) . In addition, the rate of glucose phosphorylation was found to be altered specifically in the hypothalamus after a history of hypoglycemia (11) .
Kinetic modeling of brain uptake of the glucose analog 18 F-FDG allows investigation of changes in cerebral glucose homeostasis in vivo. So far, 18 F-FDG PET studies have focused on the cerebral metabolic rate of glucose (CMR glc ) in rats. 18 F-FDG PET on mice rather than rats has a greater potential to address specific questions related to human metabolic and neurologic diseases, as the mouse is the preferred species for transgenic disease models. CMR glc can be estimated from PET data without the requirement of a highly time-resolved input function (12) . However, CMR glc provides no information on the individual contributions of transport and phosphorylation to glucose consumption. In addition, for a correct determination of CMR glc , the so-called lumped constant (LC) is indispensable, correcting for differences between 18 F-FDG and glucose with respect to transport and phosphorylation kinetics, respectively (13, 14) . LC is often used as a G p -independent parameter although the relative contributions of transport and phosphorylation may vary, depending on G p .
The key limiting factor for determining both transport and phosphorylation kinetics in mice is the small blood volume and the resulting difficulty in measuring an adequate arterial input function.
To overcome this issue, we adapted an earlier protocol for rats (15) to measurements in mice. This protocol is based on an arteriovenous shunt and a coincidence counter to record input functions with a high temporal resolution (16) . With this, the rate constants of the single processes, that is, 18 F-FDG transport and phosphorylation, are accessible.
Extending our data from normoglycemic mice (16) to data from mice undergoing insulin-induced acute hypoglycemia, we addressed the question of how acute hypoglycemia affects the kinetics of regional glucose transport and phosphorylation in the mouse brain. We evaluated whether the observed alterations are the consequences of saturation kinetics and increased CBF alone or whether additional physiologic adaptations such as alterations in barrier permeability need to be considered to model the data.
MATERIALS AND METHODS

Animal Preparation
Animal experiments were in accordance with the Swiss Animal Protection Law and were approved by the Veterinary Office of the Canton Zurich. To exclude strain-specific effects, we included 2 strains. Male CD1 (n 5 10; weight, 34.2 6 2.5 g [mean 6 SD]) and C57BL/6 (n 5 5, 27.1 6 2.8 g) mice (Charles River) were housed under standard conditions. Data from non-insulin-treated animals (n 5 14) were from recent experiments (16) . Animals were prepared as described previously for the acquisition of PET/CT and input function (16) . Briefly, catheters were inserted into the femoral artery and vein and were connected to form a closed shunt loop, which was guided through a coincidence counter (twilite; Swisstrace) and a peristaltic pump at a constant flow of 120 mL/min. Two 3-way valves were used for insulin and 18 F-FDG infusion.
Insulin Infusion and Blood Sampling
Insulin (Actrapid, 1 IU/mL; Novo Nordisk) infusion rates were dependent on the animal weight and the initial and target G p concentrations. For a mouse weighing 30 g, insulin infusion started with 9 mL/min for 1 min and then was decreased stepwise over 4 min to a constant rate of 3 mL/min. Whole-blood glucose was measured in samples of 5 mL with a blood glucose meter (Ascensia; Bayer HealthCare LLC) up to 4 times before the start of the PET scan. Blood glucose levels reached a steady state 10-15 min after infusion began. A larger arterial blood sample was drawn immediately after the PET scan. Plasma was separated by centrifugation, and G p was measured with a glucose oxidase/reflectance system (Vitros DT60 II; Ortho Clinical Diagnostics).
Imaging
PET scanning and 18 F-FDG infusion were started simultaneously when G p had reached a plateau of less than 2.5 mmol/L. The isoflurane dose was adjusted to maintain the respiratory rate at between 75 and 100 bpm, and body temperature was kept between 36.5°C and 37.3°C. PET acquisition was performed as described previously with a VISTA eXplore PET/CT scanner (GE Healthcare, 0.9-mm resolution in full width at half maximum in the center of the field of view) (16) . PET data were reconstructed to a nominal voxel volume of 0.116 mm 3 . Whole-blood radioactivity was recorded in real time with the coincidence counter and translated to plasma 18 F-FDG concentration (16) . Injected 18 F-FDG doses were 10-15 MBq (40-60 pmol) in 200 mL, resulting in plasma 18 F-FDG concentrations of less than 10 nM.
PET/CT images were coregistered with the PMOD software (PMOD Technologies Inc.) to a mouse brain template provided by PMOD. Template volumes of interest were used to generate time-activity curves for the following structures: cerebrum (362 mm 2 ), cortex (149 mm 2 ), striatum (25.8 mm 2 ), hippocampus (25.0 mm 2 ), thalamus (28.2 mm 2 ), hypothalamus (11.6 mm 2 ), and cerebellum (57.2 mm 3 ) (Supplemental Fig. 1 ; supplemental materials are available at http://jnm.snmjournals.org).
Kinetic Modeling
Time-activity curves were analyzed by 2-tissue-compartment 18 F-FDG kinetic modeling with PMOD as described previously (16) to determine the clearance K 1,FDG (mL/min per cm 3 tissue) for 18 F-FDG transport from plasma to brain and the rate constants (1/min) k 2,FDG for reverse transport, k 3,FDG for 18 F-FDG phosphorylation, and k 4,FDG for dephosphorylation (17) . Image data were corrected for blood radioactivity with a fractional cerebral blood volume of 5.5% (18) . The transport rate of glucose from plasma to tissue (T glc , mmol/min/100 g) was calculated according to Equation 1,
Eq. 1 with G p being in mmol/L and r being brain tissue density of 1.04 g/cm 3 (19) . L 1 is the ratio between K 1,FDG and K 1 of glucose (K 1,FDG /K 1,glc 5 1.48). L 1 corrects for differences in 18 F-FDG and glucose transport kinetics and was determined in nonsedated humans at a G p of 3-16 mmol/L and was about 10% lower than estimated for pentobarbitalanesthetized rats (20) (supplemental data).
Influence of CBF on K 1,glc and T glc
The extraction ratio of glucose from plasma to brain tissue (E glc ) was estimated with Equation 2. The permeability-surface area product (PS glc ), that is, K 1,glc values at infinite CBF, was extrapolated with Equation 3. Hypothetical K 1,glc at a given CBF was estimated from PS glc with Equation 4 (21):
with CPF being cerebral plasma flow, that is, the product of [1 2 hematocrit 5 0.56] (22) and CBF in mL/min/cm 3 . At a G p of more than 2 mmol/L, a CBF of 1.30 mL/min/cm 3 (averaged from (23), excluding corpus callosum) was used except for the hypothalamus, for which a CBF of 0.86 mL/min/cm 3 was used (24) . An increase in CBF by 57% (supplemental data: 0%-100%) was assumed at a G p of less than 2 mmol/L (6,25).
Michaelis-Menten Saturation Kinetics
To estimate Michaelis-Menten parameters, average G p along the capillary (G9 p ) was calculated from the arterial G p with Equation 5. The correction was not applied to G p in Equation 1, because a similar reduction in the concentration of 18 F-FDG (input function) and G p along the capillary was assumed. K 1,FDG is thus underestimated by a factor similar to G9 p /G p .
Eq. 5
Michaelis-Menten functions as shown in Equations 6 and 7 (and the supplemental data) were fit to K 1,glc and T glc , respectively, by leastsquares regression analysis (SigmaPlot, version 12.5; Systat Software Inc.). CBF. Estimated parameters were the maximal capacity (T max ), G9 p at half T max (K T ), and T max /K T (K 1,glc 1st order ) for glucose transport. Multiplication of Equation 6 by G p reveals Equation 7 .
Eq. 6
Eq. 7
Equation 6 was used correspondingly to analyze k 3,glc (L 3 5 k 3,FDG /k 3,glc 5 0.38 (20) ). T max was replaced by V max · G p /G i , the maximal phosphorylation velocity, where G p /G i is the correction factor for the ratio between G p and intracellular glucose concentration (G i ).
1st order . The 18 F-FDG uptake rate constant (K FDG ), the relative volume of distribution (V D ), and CMR glc were calculated according to Equations 8-10 with LCs as described below.
The CMR glc of the cerebrum was estimated with 3 LCs: LC1, an invariable LC of 0.6 (26, 27) ; LC2, a G p -adjusted LC derived from the values reported for awake rats by Suda et al. (13) (for this purpose, we multiplied the LC values in rats by a factor of 1.35, to reach an LC of 0.6 on average in normoglycemic animals); and LC3, the LC derived from experimental parameters as proposed by Backes et al. and shown in Equation 11 (28) , assuming L 1 5 L 2 5 1.48 and L 3 5 0.38 (20) .
Eq. 11
Estimation of Intracellular Glucose Concentration
The intracellular glucose concentration G i was iteratively estimated from G p according to Equation 12 .
Eq. 12 G p /G i at a G p of 5 mmol/L, where hexokinase I is saturated but not GLUT1, was determined by iteration; K M was 0.04 mmol/L (29) . All other parameters were fit as described above.
Statistics
The influence of brain region on single rate constants, K FDG , and CMR glc was assessed with repeated-measures ANOVA with brain region as the within-subject factor (cortex, striatum, hippocampus, thalamus, cerebellum, and hypothalamus, i.e., df 5 5). Significant F values are reported. For the purpose of post hoc testing with 2-tailed, homoscedastic t tests, data from regions with a significant within-subject effect were separated into a hypoglycemic group (G p , 2.5 mmol/L, corresponding to G9 p , 2 mmol/L) and a normoglycemic group (G p . 2.5 mmol/L). All data are shown with associated SD unless otherwise stated. The supplemental data report R 2 .
RESULTS
The insulin-clamp protocol resulted in a G p of 1.9 6 0.3 mmol/L (n 5 14, plus 1 outlier with 3.8 mmol/L because the initial infusion rate was accidentally reduced). 18 F-FDG plasma clearance was faster in hypoglycemic than normoglycemic animals (Fig. 1) .
Influence of CBF on Cerebral Glucose Transport
As shown in Figure 2A , K 1,glc (K 1,FDG /L 1 ) was highest at a low G p and decreased with increasing G p . T glc followed a typical saturation function (Supplemental Fig. 2 ). Because CBF increases abruptly at a G p of less than 2 mmol/L in rats (6,25), we first investigated to what extent a similar increase in CBF would affect K 1,glc . We assumed a 57% increase in CBF at a G p of less than 2 mmol/L from 1.30 to 2.04 mL/min/cm 3 (6, 23, 24) and estimated the corresponding hypothetic K 1,glc at 1.30 mL/min/cm 3 with Equations 2-4. Figure 2A and Supplemental Figure 3 show the uncorrected and CBF-normalized K 1,glc values. At a G p of less than 2 mmol/L (CBF, 2.04 mL/min/cm 3 ), PS ranged from 0.22 to 0.80 mL/min/cm 3 (0.40 6 0.19); at a G p of 2-3 mmol/L (CBF, 1.30 mL/min/cm 3 ), from 0.24 to 0.41 (0.33 6 0.06); and at a G p of more than 3 mmol/L, from 0.11 to 0.35 (0.22 6 0.07). E glc was between 0.14 (highest G p ) and 0.79 (lowest G p ). The estimated average increase in K 1,glc , T glc , and K FDG due to the assumed 57% increase in CBF was 9% (6%-19%). Doubling the CBF would result in an estimated average increase of 13% (7%-25%). Simulations for K 1,glc , E glc , and PS glc with CBF increases of between 0% and 100% and 2 different L 1 values are shown in Supplemental Figure 4 also shows G9 p in relation to G p . K 1,glc was additionally calculated from PS FDG /L 1 to evaluate possible artifacts due to CPF-limited transport when K 1,FDG /K 1,glc approaches 1 and K 1,FDG /L 1 underestimates K 1,glc (Supplemental Fig. 7) .
Influence of Glucose Concentration on Transport and Phosphorylation
The K 1,glc and T glc of the cerebrum were further analyzed with Michaelis-Menten saturation kinetics. To normalize for changes in CBF, K 1,glc and T glc values at a G p of less than 2 mmol/L were estimated for physiologic CBF as described above. The fit parameters obtained with Equations 6 and 7 are shown in Figure 2A and Supplemental Figures 4, 5, and 7 for CBF increases of between 0% and 100% and for L 1 values of 1.48 (humans) and 1.66 (pentobarbitalanesthetized rats). Depending on L 1 and the assumed CBF increase at a G p of less than 2 mmol/L, K t varied between 6.7 6 2.5 mmol/L (L 1 5 1.48, no CBF increase) and 9.3 6 2.9 mmol/L (L 1 5 1.48, 100% CBF increase) and T max between 215 6 62 mmol/min/100 g (L 5 1.66, no CBF increase) and 289 6 71 mmol/min/100 g (L 5 1.48, 100% CBF increase).
The efflux rate constant k 2 scattered between 0.11 and 0.76/min and did not correlate with G p (Supplemental Fig. 8 ). To visualize the influence of G p on glucose partitioning at the BBB, the partition coefficient K 1,FDG /k 2,FDG was plotted versus G9 p (Fig. 2B) . Net glucose partitioning from plasma to brain was higher in hypoglycemia than normoglycemia.
Plotting k 3,glc over G9 p showed a sharp increase in k 3,glc at a G9 p of less than 2.0 mmol/L (G p , 2.5 mmol/L; Fig. 2C ). Fit parameters of the analysis with Equation 6 are shown in Figure 2C . The intracellular balance between 18 F-FDG phosphorylation (k 3,FDG · G i ) and efflux (k 2,FDG · G i ) is shown in Figure 2D (k 3,FDG /k 2,FDG ) . The ratio k 3,FDG /k 2,FDG was not influenced by a G p of above 2.5 mmol/L but was significantly increased below 2.5 mmol/L (G9 p , 2 mmol/L) (k 3 /k 2 5 0.24 6 0.10, n 5 14, at euglycemia, vs. 0.87 6 0.60, n 5 14, at G p , 2.5 mmol/L; P , 0.001). Dephosphorylation of FDG-6-phosphate as described by k 4,FDG was significantly different from zero in all animals, with high scattering and no obvious dependence on G p (Supplemental Fig. 9 ). K FDG and V D were derived from the single rate constants and showed respective patterns ( Fig. 3 and Supplemental Fig. 10) . Both increased when G p was reduced. Figure 4A shows the LCs as described in the "Materials and Methods" section. When estimated with a fixed LC of 0.6, CMR glc was independent of G p (60 6 5 vs. 51 6 6 mmol/min/100 g in animals with a G p greater and less than 2.5 mmol/L, respectively) despite the significant increases in T glc (Supplemental Fig. 2 ) and k 3,FDG · G p (not shown) with increasing G p . However, when LC2 or LC3 was applied, the average CMR glc in animals with a G p of more than 2.5 mmol/L was higher in all brain structures examined than the average CMR glc in animals with a G p of less than 2.5 mmol/L (all P , 0.003, Table 1 ; Figs. 4B and 4C).
Brain-Region-Specific Response to Hypoglycemia
Brain region had a significant influence on K 1,FDG (F 5 7.468, P , 0.0005), K FDG (F 5 14.346, P , 0.0005), and CMR glc (F 5 24.523, P , 0.0005) but not on k 2,FDG , k 3,FDG , and k 4,FDG (all P . 0.28). CMR glc was estimated with LC1 in this analysis. The use of either LC2 or LC3 yielded the same conclusion. Pairwise comparison showed significantly lower K FDG and CMR glc in the hypothalamus and cortex than in any other brain region included in the analysis. In addition, K 1,FDG was lower in the hypothalamus than in any other structure. The differences in K 1,FDG and K FDG between the hypothalamus and other brain regions were dependent on G p : although K 1,FDG and K FDG were not significantly different between brain regions at a G p of more than 2.5 mmol/L, they were less increased (by 15% and 19%) under hypoglycemia in the hypothalamus than in other brain structures. The findings in the cortex were similar (12% and 17% less increase for K 1,FDG and K FDG , respectively). These findings are summarized in Table 2 , and dot-box plots are shown in Supplemental Figure 11 . Differences in CMR glc between the regions were independent of G p , that is, there was no region · G p interaction influencing CMR glc . K 1,glc , T glc , and k 3,glc of the respective brain regions were fit to G9 p with Equations 6 and 7. Figure 5 , Supplemental Figure 12 , and Supplemental Figure 13 show the respective data and fits for glucose transport. As found for the cerebrum ( Fig. 2A and Supplemental Fig. 2) , transport in the cortex, striatum, hippocampus, and thalamus followed typical saturation kinetics. However, plots from the cerebellum and in particular the hypothalamus had a less pronounced shape of saturation. When fit with both Equation 6 and Equation 7, the hypothalamus had the highest T max and K T at the lowest K 1,glc 1st order of all studied regions (Fig. 5, Supplemental  Fig. 12 , and Supplemental Fig. 13 ). This case was also true when K 1,glc was calculated via PS glc /L 1 (assuming a 57% CBF increase at a G p of less than 2 mmol/L) and when normalization was to 1.3 instead of 0.86 mL/min/cm 3 CBF, indicating that CBF was not responsible for these observations. The hypothalamus thus has the highest glucose influx at a high G p but the lowest influx under hypoglycemia. Region-specific k 3,glc as a function of G9 p had similar patterns for all investigated brain regions (Supplemental Fig. 14) .
Estimation of Intracellular Glucose Concentrations
The estimated cerebral and hypothalamic G i is shown in Figure  6 as a function of G p . Although the estimated G i was similar in both brain regions at a G p of 6.4 mmol/L (i.e., G i 5 2.0 mmol/L), it was lower in the hypothalamus than in the cerebrum at a lower G p but higher at a G p of more than 6.4 mmol/L. The estimated V max of phosphorylation (Eq. 12) was 67.4 and 61.0 mmol/min/ 100 g for the cerebrum and hypothalamus, respectively. These values are close to the CMR glc values reported in Table 1 .
DISCUSSION
Applying our recently published technique for highly timeresolved monitoring of the 18 F-FDG input function in mice (16), we investigated glucose transport and phosphorylation kinetics in mouse brain under acute insulin-induced hypoglycemia. We were able to assign the increase in K 1,glc under hypoglycemia to 2 mechanisms. First, our simulations revealed that the expected increase in CBF at a G p of less than 2 mmol/L (6,25) caused an increase in K 1,glc , T glc , and K FDG by 6%-19%. The elevation in CBF as a response to hypoglycemia was thus effectively improving glucose delivery to the brain parenchyma. In fact, as shown by Equations 2-4, the higher the K 1,glc and therefore E glc were, the stronger was the effect of CBF elevation on glucose transport.
After correction for the effect of CBF elevation at a low G p , even when assuming doubling of CBF, cerebral K 1,glc values were still higher at low than high G p , and T glc followed a typical saturation function when plotted against G9 p . This finding was expected, as the apparent K T of GLUT1, the major GLUT isoform at the BBB, lies within the studied range of G p . The fitted K T and T max were in the range of published values for rats (1,6,30,31). Applying L 1 determined with pentobarbital-anesthetized rats instead of L 1 determined with nonsedated humans reduced T max by about 10% without affecting K t . We analyzed our data with the standard (irreversible) Michaelis-Menten model, not taking into account product inhibition-that is, transport inhibition or reversible transport at significant glucose levels on the trans side of the transporter (6) . This explains the relatively high (apparent) K T values when compared with experiments under zero trans conditions (6, 31) . Another simplification was that we assumed only a single mechanism for glucose transport and did not consider additional saturable or nonsaturable routes (32) . Regarding k 2 , we did not expect a marked influence of G p , as intracellular glucose levels were assumed to be below the apparent K T of GLUT1. Translocation of GLUT1 to the plasma membrane at a low G p (8) would result in an increase in k 2 under hypoglycemia. This possibility was not supported by our data, although the high scattering in k 2 would not allow detection of minute changes.
Hexokinase type I is the major hexokinase isoform in the brain (33) . The enzyme is saturated under normoglycemia, because (29, 34) . G9 p at the half maximal phosphorylation rate was 2.3 mmol/L. This value is close to the reported G p of 2 mmol/L in rats, at which intracellular glucose becomes depleted (6, 34 ). It appears plausible that in our experiments intracellular glucose levels reached the K M of hexokinase I at a G9 p of 2.3 mmol/L, resulting in an increase in k 3,glc . Our simulation of G i in the cerebrum revealed that G i equals 149 mmol/L at a G9 p of 2.3 mmol/L. G i was 40 mmol/L at a G9 p of 1.3 mmol/L. Taking into account the several assumptions made for this analysis and the uncertainty of the fits at a low G9 p , our results support our hypothesis that the CBF increase and saturation kinetics alone can describe the physiologic responses to hypoglycemia in the mouse brain, including intracellular depletion of glucose at a G p of less than 2 mmol/L.
One of our key findings is that both brain glucose transport and phosphorylation rate constants determined with 18 F-FDG PET depend on G p . This finding is in agreement with predictions from theoretic analysis of the glia-vascular unit (1) and is supported by MR spectroscopy data (31) but is in contrast to other PET studies (27, 35) . A main reason for the discrepancies from previous PET studies lies in the choice of the LC (13, 14) , in particular under hypoglycemia. The influence of G p was different on K 1,FDG and k 3,FDG . As CMR glc depends on both parameters, LC is not a constant but is dependent on G p . Determining K 1,FDG -k 3,FDG helps to avoid misinterpretations of 18 F-FDG PET results by comparing CMR glc values calculated with inaccurate LC values. LC3 (28) allows G p -dependent LC values, provided that species-specific L 1 to L 3 is available. However, L 1 should be defined as PS FDG /PS glc to take into account the influence of CBF on K 1,FDG /K 1,glc , as this ratio approaches 1 when CBF becomes rate-limiting. Alternatively, and to validate LC3, experimentally determined LC values are required for mice over a broad G p range, as done thus far in awake rats (LC2) (13) .
The ratio T max /CMR glc was constant under euglycemia in various nuclear magnetic resonance experiments. In rats anesthetized with a-chloralose and enflurane, the ratio was 4.5-4.7 and 5.8, respectively, estimated with the irreversible Michaelis-Menten model (6, 31) . T max /CMR glc in mouse cerebrum in our study was 4.2 (LC2) and 4.1 (LC3), respectively, which is in the range of published values for rats.
We found a peculiar pattern for glucose transport in the hypothalamus. Both K 1,glc -and T glc -versus-G9 p plots indicated a transport mechanism with either high K T or absence of saturability within the studied G p range. At high but not low G p , this finding is in line with reports of a less restrictive BBB for glucose in this brain region (34) . Our high K T would be in agreement with the reported presence of GLUT2 in the hypothalamus (36) . The K T of GLUT2 is around 17 mmol/L (37). However, the contribution of GLUT2 to overall glucose transport in the hypothalamus is not known. Under hypoglycemia, glucose transport was lowest in the hypothalamus as judged from K 1,glc 1st order and K 1,glc . However, the absolute numbers of the regional analysis must be interpreted with caution considering the strong scattering in the data, spillover, and partial-volume effects.
Decreased 18 F-FDG uptake in the hypothalamus was also observed in humans under hypoglycemia (38) . Both observations of high transport at high G p and low transport at low G p , with the resulting effects on G i as simulated in this study, are of interest in the context of the suggested mechanism of glucose sensing in the hypothalamus by an intracellular glucose-binding sequence of GLUT2 (9, 39) . Signaling could be effective at both extremes of G p .
We cannot exclude a pharmacologic influence of insulin on the measured parameters. Insulin increases cortical blood flow in rats at doses of 120 ng/mL in superfused cerebral spinal fluid (40) . We may induce similar insulin levels in cerebral vessels. However, our dataset included a hypoglycemic animal without insulin treatment and a normoglycemic one that received a lower insulin dose. Both datasets were in agreement with the others. Horinaka et al. (25) showed that insulin administered under euglycemia had no effects on CBF, and previous studies suggested no direct influence of insulin on K FDG (35) . Isoflurane anesthesia has a significant influence on cerebral glucose metabolism. Our findings, therefore, cannot be directly translated to awake mice or mice under different anesthesia.
CONCLUSION
Glucose plasma-to-brain clearance and phosphorylation rate constant were increased under hypoglycemia. The alterations, including intracellular depletion of glucose, can be quantitatively described taking into account increased CBF and saturation kinetics of GLUT and hexokinase. In contrast to other brain regions, glucose transport in the hypothalamus did not show significant saturation and was lower under hypoglycemia but higher at a high G p than in other brain regions. This could contribute to the reported glucose-sensing function of the hypothalamus.
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